Navigation Links
Producing medicines in plant seeds

Using plants to produce useful proteins could be an inexpensive alternative to current medicine production methods. Researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) at Ghent University have succeeded in producing in plant seeds proteins that have a very strong resemblance to antibodies. They have also demonstrated that these antibody variants are just as active as the whole antibodies that occur naturally in humans. By virtue of their particular action, antibodies are very useful for therapeutic and diagnostic applications. From this research, it is now also clear that these kinds of antibody variants can be used in medical applications and that it is possible to produce them in the seeds of plants, which can have enormous advantages over conventional production methods.

Production of biotech medicines

A large number of today's medicines are made with the aid of biotechnology (and this number should only grow in the future). To do this, scientists use genetically modified bacteria, yeasts, or animal cells that are able to produce human proteins. These proteins are then purified and administered as medicines. Examples of such proteins are antibodies, which can be used, for instance, in the treatment of cancer. The conventional methods for producing antibodies work well, but they are expensive and have a limited production capacity. The high costs are primarily due to the need for well-equipped production labs and to the labor-intensive upkeep of the animal cells, which are needed as production units.

Plants: a possible alternative?

For a number of years now, the VIB researchers in Ghent - Bart Van Droogenbroeck, Ann Depicker and Geert De Jaeger- have been searching for ways to have plants produce useful proteins efficiently. Plants do offer a lot of advantages over conventional production methods. Because production with plants doesn't require expensive high-tech laboratories, scientists anticipate that, by working with plants, production costs will be 10 to 100 times lower. Another important advantage is that large-scale production is possible without having to make additional investments in expensive fermentors.

A good yield guaranteed

Several years ago, Geert De Jaeger and his colleagues succeeded in achieving a high yield of an antibody variant in plants, which had been very difficult to do up to that time. The trick the researchers used was to modify the plants in such a way that they would produce the antibody variant in their seeds. With their special technique, the scientists succeeded in producing seeds in which the desired protein is good for more than one third of the total protein amount. This is a huge proportion compared to other systems - normally, scientists succeed in replacing only 1% of the plant's proteins by the desired protein.

Plant seeds are especially attractive as production units. In addition to a high production capacity, they offer other important advantages over other parts of the plant. The seeds can be stored for a long time without losing the produced protein's effectiveness, so that a reserve can always be kept on hand. This means that the proteins can be isolated from the seeds at the moment that they are actually needed. With production in leaves, for example - or with conventional production methods - such lengthy storage is not possible: the protein must be isolated immediately after production. So, production in plant seeds provides the clear advantage of timely processing.

High production of an efficient antibody variant

The antibody variant that has been produced by Geert De Jaeger and his team has a very simple structure and has only one binding place for a particular substance. Bart Van Droogenbroeck and his colleagues, under the direction of Ann Depicker, are now showing that it is also possible to produce more complex antibody variants in la rge quantities in the seeds of the Arabidopsis plant. Over 10% of the proteins in the seeds of these plants are the desired antibody variant. As is the case with whole antibodies, these more complex antibody variants have two binding places for a specified substance. This close similarity to whole antibodies makes these antibody variants extremely useful for therapeutic and diagnostic applications.

However, the production of proteins in plants is completed in a different way than in humans. Therefore, to be certain that this different completion process does not affect the effectiveness of the potential medicine; the scientists have subjected the action of the antibody variant to an exhaustive battery of tests. These laboratory tests have shown that the antibody variants produced in plants are just as effective as whole human antibodies in protecting animal cells against infection with the Hepatitis A virus.

This is a significant step forward in making protein production in plants a real alternative to current production methods.
'"/>

Source:VIB, Flanders Interuniversity Institute of Biotechnology


Related biology news :

1. Producing bio-ethanol from agricultural waste a step closer
2. MIT chemist discovers secret behind natures medicines
3. Protect patients from exploitation by alternative medicines industry
4. Key molecule in plant photo-protection identified
5. Transplantation Of Monkey Embryonic Stem Cells Reverses Parkinson Disease In Primates
6. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
7. Circles Of DNA Might Help Predict Success Of Stem Cell Transplantation
8. Antibodies from plants protect against anthrax
9. New RNA polymerase discovered in plants
10. Implanted Devices Detect High-Risk Heart Failure Patients
11. Ophthalmologists implant five patients with artificial silicon retina microchip

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: